Upgrade to SI Premium - Free Trial

Biohaven Pharma (BHVN)

11.10 -0.30 (2.63%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/3/26)
- M&A (3/31/23 *Est)

Latest Headlines

Biohaven begins first human trial of brain-penetrant drug BHV-8100 June 1, 2026 7:31 AM - StreetInsider Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation June 1, 2026 7:30 AM - PR NewsWire Form 8-K Biohaven Ltd. For: May 26 May 27, 2026 5:15 PM - SEC Filing Raymond James on Biohaven Pharma (BHVN) with shares up 7%: 'Promising Degrader Data Sets Ahead of R&D Day' May 27, 2026 10:16 AM - StreetInsider Biohaven reports positive patient data for autoimmune disease drugs May 27, 2026 7:31 AM - StreetInsider Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Dise May 27, 2026 7:30 AM - PR NewsWire Biohaven shares clinical data on epilepsy drug opakalim May 26, 2026 7:31 AM - StreetInsider Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile May 26, 2026 7:30 AM - PR NewsWire Form SCHEDULE 13G/A Biohaven Ltd. Filed by: JANUS HENDERSON GROUP PLC May 15, 2026 12:37 PM - SEC Filing Biohaven Pharma (BHVN) PT Lowered to $18 at Morgan Stanley May 13, 2026 8:19 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN) May 12, 2026 6:52 AM - StreetInsider Form 8-K Biohaven Ltd. For: May 04 May 5, 2026 4:18 PM - SEC Filing Biohaven Pharma (BHVN) PT Lowered to $22 at RBC Capital May 5, 2026 6:29 AM - StreetInsider Biohaven Pharma (BHVN) Misses Q1 EPS by 4c May 4, 2026 5:11 PM - StreetInsider Form 424B5 Biohaven Ltd. May 4, 2026 5:08 PM - SEC Filing Biohaven Pharma (BHVN) files mixed shelf May 4, 2026 4:26 PM - StreetInsider Form S-3ASR Biohaven Ltd. May 4, 2026 4:24 PM - SEC Filing Form 10-Q Biohaven Ltd. For: Mar 31 May 4, 2026 4:08 PM - SEC Filing Form 8-K Biohaven Ltd. For: May 04 May 4, 2026 4:07 PM - SEC Filing Form 8-K Biohaven Ltd. For: Apr 28 May 4, 2026 4:02 PM - SEC Filing Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results May 4, 2026 4:02 PM - PR NewsWire Form 4 Biohaven Ltd. For: Apr 28 Filed by: Mehta Kishan April 30, 2026 8:10 PM - SEC Filing Form 4 Biohaven Ltd. For: Apr 28 Filed by: Bailey Gregory April 30, 2026 8:09 PM - SEC Filing Form 4 Biohaven Ltd. For: Apr 28 Filed by: Heffernan Michael Thomas April 30, 2026 8:09 PM - SEC Filing Form 4 Biohaven Ltd. For: Apr 28 Filed by: Antonijevic Irina April 30, 2026 8:08 PM - SEC Filing Form 4 Biohaven Ltd. For: Apr 28 Filed by: CHILDS JOHN W April 30, 2026 8:08 PM - SEC Filing Form 4 Biohaven Ltd. For: Apr 28 Filed by: HUGIN ROBERT J April 30, 2026 8:08 PM - SEC Filing Form 4 Biohaven Ltd. For: Apr 28 Filed by: GREGORY JULIA P April 30, 2026 8:07 PM - SEC Filing Canaccord Starts Biohaven Pharma (BHVN) at Buy April 13, 2026 5:18 AM - StreetInsider Biohaven Pharma (BHVN) PT Raised to $17 at Citi April 2, 2026 5:09 AM - StreetInsider Form 4 Biohaven Ltd. For: Mar 17 Filed by: Mehta Kishan March 19, 2026 6:18 PM - SEC Filing Biohaven completes enrollment in phase 2 obesity study March 19, 2026 7:30 AM - StreetInsider Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment March 19, 2026 7:30 AM - PR NewsWire Biohaven Pharma (BHVN) PT Raised to $28 at Jefferies March 16, 2026 5:28 PM - StreetInsider Form DEFA14A Biohaven Ltd. March 13, 2026 4:58 PM - SEC Filing Form DEF 14A Biohaven Ltd. For: Apr 28 March 13, 2026 4:55 PM - SEC Filing Biohaven Pharma (BHVN) PT Raised to $30 at TD Cowen March 11, 2026 9:23 AM - StreetInsider Form 4/A Biohaven Ltd. For: Mar 04 Filed by: CHILDS JOHN W March 9, 2026 6:12 PM - SEC Filing Raymond James on Biohaven Pharma (BHVN): 'results continue to highlight an opportunity for opakalim' March 9, 2026 1:55 PM - StreetInsider uniQure stock surges 36% on FDA official’s departure March 9, 2026 7:57 AM - StreetInsider Full Article List